Blood Tests

Chronic alcohol consumption is strongly associated with disruption of the blood–brain barrier (BBB), neuroinflammation, and long-term cognitive decline. Even moderate but sustained drinking can cause subtle but measurable molecular changes that increase vulnerability to neurodegeneration, mood disorders, and memory impairment. The Alcohol Use Disorder-Dx service applies the BBBNeuro-Dx biomarker platform to detect alcohol-related BBB disruption patterns, giving patients and providers objective insight into the neurological impact of alcohol use.

Exposure to environmental toxins, industrial chemicals, heavy metals, or certain pharmaceuticals can weaken the blood–brain barrier (BBB) and trigger neuroinflammation, oxidative stress, and progressive cognitive decline. The Neurotoxicity-Dx service interprets BBBNeuro-Dx biomarker results to identify patterns of molecular damage linked to toxic exposures, providing patients and physicians with early, actionable insights.

Traumatic brain injury (TBI) is one of the leading causes of long-term neurological disability worldwide. Even when initial symptoms appear mild, the underlying molecular damage can disrupt the blood–brain barrier (BBB), trigger neuroinflammation, and set the stage for chronic neurological complications. The Traumatic Brain Injury-Dx service leverages the BBBNeuro-Dx test to detect biomarker patterns specific to brain trauma. By identifying molecular signatures of BBB disruption, inflammation, and neuronal injury, this service enables early diagnosis, supports clinical decision-making, and helps monitor long-term recovery.

Atrial fibrillation (AFib) is the most common sustained cardiac arrhythmia and a leading cause of stroke, heart failure, and reduced quality of life. Structural remodeling of the atria, inflammation, and metabolic stress are major contributors to AFib development. The Atrial Fibrillation-Dx service interprets CARMD-Dx biomarker results to identify molecular signatures of atrial stress, immune activity, and cardioembolic risk. This empowers clinicians to detect AFib risk earlier, personalize care strategies, and monitor disease progression.

Cardioembolic strokes occur when blood clots form in the heart—often due to atrial fibrillation or other structural changes—and travel to the brain, blocking blood flow. These strokes tend to be more severe and recurrent, making early detection and prevention critical. The Cardioembolic Stroke-Dx service interprets CARMD-Dx biomarker results to identify molecular signals of atrial remodeling, clotting risk, and vascular stress associated with cardioembolic stroke. By detecting risk early, this service supports proactive intervention strategies that can save lives.

The heart and brain are closely connected through the neurocardiac axis, a complex communication system involving autonomic nerves, circulation, and molecular signaling. When disrupted, this axis can contribute to stroke, arrhythmias, cognitive decline, and systemic dysfunction. The Neurocardiac-Dx service interprets CARMD-Dx biomarker results to identify molecular patterns linking cardiac stress to neurological impact. This helps clinicians uncover hidden heart–brain risks and tailor precision care strategies.

Regular endurance training strengthens the heart, but in some athletes, prolonged or intensive exercise can cause atrial remodeling that resembles early signs of cardiovascular disease. Distinguishing between healthy athletic adaptation and pathological remodeling is critical for protecting long-term heart health while supporting peak performance. The Sportive Heart-Dx service interprets CARMD-Dx biomarker results to evaluate cardiac stress, remodeling patterns, and vascular function in athletes and highly active individuals. This helps identify when changes are beneficial training adaptations versus early warning signs of potential pathology.

The Foundational Health-Dx service provides a broad-spectrum molecular assessment of the body’s key systems—immune, metabolic, cardiovascular, and neurological. This test is designed to establish a comprehensive health baseline, helping individuals understand their unique biomarker profile and identify early risk factors for chronic disease. With insights from this service, patients and clinicians can take proactive steps toward long-term wellness, optimize treatment plans, and monitor progress over time.

The gut and the brain are connected through a complex communication network known as the gut–brain axis. Imbalances in gut health—such as dysbiosis, leaky gut, or chronic inflammation—can influence mood, cognition, and neurological function. Likewise, neurological stress can disrupt gut function, creating a cycle that impacts overall wellness. The Gut–Brain Health Axis-Dx service interprets FDHLTH-Dx biomarker results to assess how gut function and brain health interact. By measuring biomarkers linked to inflammation, microbial imbalance, and neurological signaling, this service provides critical insight into conditions ranging from digestive disorders to mood disturbances and cognitive decline.

Many individuals recovering from COVID-19 experience lingering health issues, commonly referred to as Long COVID or Post-Acute Sequelae of SARS-CoV-2 infection (PASC). These symptoms may include fatigue, brain fog, shortness of breath, cardiovascular changes, and neurological issues that persist long after the initial infection has resolved. The Long COVID-Dx service interprets FDHLTH-Dx biomarker results to detect ongoing immune, metabolic, and inflammatory disruptions caused by COVID-19. This allows for a deeper understanding of post-viral complications and provides actionable guidance for recovery strategies.

Cardiometabolic syndrome is a cluster of conditions—including obesity, hypertension, insulin resistance, and dyslipidemia—that together increase the risk of heart disease, stroke, and diabetes. Often silent in its early stages, the syndrome develops over years as immune and metabolic pathways become imbalanced. The Cardiometabolic Syndrome-Dx service leverages IMMUNOMET-Dx biomarker analysis to identify molecular patterns of systemic dysfunction long before complications arise. This empowers patients and physicians to intervene early with lifestyle, nutritional, and therapeutic strategies.

Cardiometabolic syndrome is a cluster of conditions—including obesity, hypertension, insulin resistance, and dyslipidemia—that together increase the risk of heart disease, stroke, and diabetes. Often silent in its early stages, the syndrome develops over years as immune and metabolic pathways become imbalanced. The Coronary & Peripheral Vascular Insufficiency-Dx service interprets IMMUNOMET-Dx biomarker results to detect these early molecular warning signs, helping prevent serious outcomes such as heart attack, stroke, or limb ischemia.

Breast cancer remains one of the most common cancers worldwide, but its progression is shaped not only by genetic mutations but also by the immune system’s interaction with developing tumors. Subtle molecular and immune changes often appear long before tumors become visible on imaging, providing an opportunity for earlier detection and intervention. The Breast Immunocarcinogenic Assay analyzes biomarker patterns that reveal immune system activation, tumor-promoting inflammation, and prometastatic signaling. This assay provides clinicians with actionable molecular insights to guide risk assessment, early diagnosis, and personalized care strategies.

Cervical cancer often develops gradually, progressing from precancerous lesions influenced by persistent HPV infection and immune system dysregulation. While Pap smears and HPV tests are important tools, they may not capture the earliest molecular immune responses that precede cancer development. The Cervical Immunocarcinogenic Assay provides a biomarker-based evaluation of immune activity and tumor-promoting inflammation associated with cervical carcinogenesis. This test offers clinicians and patients a more complete picture of risk, aiding early detection, treatment decisions, and long-term monitoring.

Cholangiocarcinoma, or bile duct cancer, is an aggressive and often late-diagnosed cancer of the biliary tract. Early stages typically present with few or nonspecific symptoms, making early molecular detection critical for improving outcomes. The Cholangio Immunocarcinogenic Assay evaluates immune and molecular biomarker activity linked to bile duct carcinogenesis. By detecting subtle immunocarcinogenic and prometastatic patterns, this test supports early risk identification, precision therapy guidance, and recurrence monitoring.

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. While traditional screenings such as colonoscopy and fecal testing are critical, they often detect cancer after it has already developed. Prometastatic molecular changes, however, can occur much earlier as the tumor microenvironment evolves. The Colorectal Carcinoma Prometastatic Assay evaluates biomarker patterns of immune dysregulation, prometastatic signaling, and tumor-driven inflammation that drive colorectal cancer progression and metastasis. This assay supports earlier detection, treatment guidance, and recurrence monitoring.

Diffuse Large B Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and is highly aggressive if untreated. Traditional diagnostics rely heavily on histopathology and imaging, which often detect disease at later stages. The DLBCL Assay focuses on immune and molecular biomarkers that signal lymphoma development and progression. By identifying these patterns, the assay provides early diagnostic support, treatment guidance, and recurrence monitoring, improving the outlook for patients with or at risk for DLBCL.

Ocular melanoma, also known as uveal or eye melanoma, is a rare but aggressive cancer that develops in the eye’s pigment cells. Because it often progresses silently, many patients are not diagnosed until later stages when treatment options are more limited. The Eye Immunomelanoma Assay evaluates immune and prometastatic biomarker activity specific to ocular melanoma. By detecting these molecular changes early, the assay provides clinicians with critical insights for risk assessment, treatment guidance, and recurrence monitoring.

The liver is a frequent site of both primary cancer development and metastasis from other tumors. Prometastatic molecular activity in the liver microenvironment can create conditions that allow cancerous cells to thrive and spread. Detecting these changes early is critical for preventing progression and improving treatment outcomes. The Hepatic Prometastatic Reaction Assay analyzes immune-molecular and prometastatic biomarker activity in the liver environment. This test provides early insight into tumor-promoting conditions, helping clinicians anticipate risk, tailor interventions, and monitor long-term liver-related cancer dynamics.

Kidney cancer (renal cell carcinoma) often develops silently, with few symptoms until later stages. By the time it is clinically detected, disease progression may already be advanced. Molecular and immune system disruptions, however, begin much earlier. The Kidney Immunocarcinogenic Assay evaluates immune and prometastatic biomarker patterns associated with kidney tumor development and progression. This test enhances traditional imaging and pathology by providing immune-molecular insight into early disease activity, recurrence risk, and treatment response.

Lung cancer is the leading cause of cancer-related deaths worldwide, often detected at advanced stages when treatment options are limited. Subtle immune and prometastatic molecular changes, however, can appear much earlier than tumors become visible on imaging. The Lung Immunocarcinogenic Assay measures immune checkpoint activity, inflammatory signaling, and prometastatic biomarker patterns that contribute to lung cancer development and progression. This test supports earlier detection, precision therapy selection, and recurrence monitoring.

Pancreatic cancer is one of the most lethal cancers due to its late diagnosis and aggressive progression. Traditional imaging and pathology often miss early molecular events, leaving few options for early intervention. The Pancreas Immunocarcinogenic Assay evaluates immune system activity and prometastatic biomarker patterns linked to pancreatic carcinogenesis. By analyzing these molecular signals, this test enables earlier risk identification, therapy guidance, and recurrence monitoring, even in patients without advanced symptoms.

Melanoma is the most aggressive form of skin cancer, driven by both genetic mutations and immune system interactions in the skin microenvironment. While visual inspection and biopsy remain standard, subtle molecular changes in immune activity often appear earlier, offering new opportunities for detection and treatment guidance. The Skin Immunomelanoma Assay evaluates immune checkpoint activity, inflammatory signaling, and prometastatic biomarker patterns associated with melanoma. This test provides clinicians with a molecular-level perspective to support early diagnosis, precision treatment, and recurrence monitoring.